Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BVC4
UPID:
LST8_HUMAN
Alternative names:
G protein beta subunit-like; Mammalian lethal with SEC13 protein 8
Alternative UPACC:
Q9BVC4; B3KMM4; B4DY00; D3DU88; Q5M800; Q86Y18; Q8WUI5; Q9HA66; Q9UJV6
Background:
The Target of rapamycin complex subunit LST8, also known as G protein beta subunit-like and Mammalian lethal with SEC13 protein 8, plays a pivotal role in cell growth and survival. It is a crucial component of both mTORC1 and mTORC2 complexes, influencing protein synthesis, ribosome synthesis, and actin cytoskeleton regulation through various signaling pathways, including AKT1-mediated phosphorylation and amino acid signaling.
Therapeutic significance:
Understanding the role of Target of rapamycin complex subunit LST8 could open doors to potential therapeutic strategies.